Concord Biotech has announced that a meeting of its Board of Directors will convene on February 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The results will be reviewed by the Statutory Auditors, and other business matters will be discussed during the meeting. The trading window remains closed until 48 hours after the results are declared.
Board to Review Q3 Results
A meeting of the Board of Directors at Concord Biotech is scheduled for February 11, 2026. The primary agenda is to review and approve the Standalone and Consolidated Unaudited Financial Results for the Q3 (Oct-Dec) and nine-month period ending December 31, 2025.
Financial Result Review
During the meeting, the board will review the unaudited financial results. Following the review, the Statutory Auditors’ report will be presented, allowing for discussions on other relevant business matters.
Trading Window Closure
As previously announced on December 26, 2025, the trading window for company securities remains closed. This restriction will stay in effect until 48 hours after the declaration of the Financial Results for the quarter and nine-month period concluding on December 31, 2025. This measure ensures compliance with regulations concerning insider trading.
Source: BSE
